权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Fetal Hepatocyte Phenotype and Cell-Based Therapy for Liver Disease

胎儿肝细胞表型和肝病细胞治疗

基本信息

批准号：
9222004
负责人：
Philip A. Gruppuso
金额：
$ 34.74万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9222004
关键词：
1-Phosphatidylinositol 3-Kinase Adult Advanced Development Area Artificial Liver Behavior Biogenesis Biological Biology Cell Cycle Cell Cycle Progression Cell Lineage Cell Therapy Cells Characteristics Chromatin Structure Development Device or Instrument Development Disease Embryo Endothelial Cells Engraftment Epigenetic Process Event FRAP1 gene Fetal Liver Fetus Gene Expression Gene Expression Regulation Genes Genetic Genome Goals Growth Health Hepatic Hepatocarcinogenesis Hepatocyte Histones Human In Vitro Injury Laboratories Leucine Life Liver Liver diseases Location MAPK3 gene Metabolic Metabolic Diseases Metabolism Methods Mitogens Molecular Newborn Infant Nutrient Pathway interactions Peptide Hydrolases Perinatal Phenotype Physiology Population Post-Translational Protein Processing Pregnancy Process Rattus Recovery Regulation Resistance Ribosomes Rodent Role Signal Pathway Signal Transduction Sirolimus Testing Translations Transplantation Variant base bile ductular cell behavior cell type cholangiocyte curative treatments epigenetic regulation fetal fetus cell in vivo inhibitor/antagonist injured innovation insight liver cell proliferation liver development liver function liver injury mature animal multipotent cell novel postnatal public health relevance

项目摘要

DESCRIPTION (provided by applicant): Growth and functional differentiation of the liver are critical to late gestation fetal metabolism, the perinatal transition and metabolic adaptation by the newborn. The biology of fetal liver development also has implications for regulation of fetal somatic growth, hepatic carcinogenesis, and cell-based therapy for liver disease. Our laboratory has long focused on late gestation liver development in the rodent. In doing so, we have identified a fetal hepatocyte phenotype that is defined by the signaling pathways that regulate fetal hepatocyte growth, proliferation and gene expression. More recently, we demonstrated the ability of late gestation fetal rat liver cells possessing a key hepatocyte marker, leucine amino peptidase (LAP), to repopulate an injured adult liver. This is a capacity not shared by adult rat hepatocytes. The present proposal is based on the central hypothesis that histone variants and histone posttranslational modifications (PTMs), acting through effects on chromatin structure, account for the signaling phenotype of late gestation fetal rat hepatocytes and the persistence of this phenotype following transplantation into the adult liver microenvironment. The long term goal of the project is to identify genetic and epigenetic mechanisms that account for the novel characteristics of fetal liver cells, thereby applying an understanding of fetal liver development o the development of cell-based therapy for liver disease. This goal will be pursued through three Specific Aims. Specific Aim 1 is to identify a fetal hepatocyte epigenetic signature by examining chromatin structure, histone variants and histone PTMs in liver during late fetal versus adult life Specific Aim 2 is to characterize the functional relationship between histone variants, histone PTMs, chromatin structure and regulation of key growth-regulating genes in liver during the fetal to adult transition. This aim will test the hypothesis that specific histone variants and PTMs are associated with developmental changes in critical growth-regulating genes. In Specific Aim 3, we will assess the role of the epigenetic signature identified in Aims 1 and 2 in defining and maintaining the ability of late gestation fetal rat liver cells to repopulate an injured adult rat iver. This aim will test the hypothesis that a fetal hepatic epigenetic signature is characteristic of a subpopulation of fetal hepatocytes that possess both hepatocyte and bile ductular markers, and that this epigenetic signature is present both before transplantation and after engraftment. Completion of these aims will provide insight into molecular mechanisms that determine cell behavior in the developing liver while advancing the development of cell-based therapy for liver disease. The project is innovative in a number of aspects. We will generate new information regarding the epigenetic regulation of gene expression during liver development. In doing so, we will characterize a previously unidentified, multipotent cell population in fetal liver that can repopulate an injured adult liver. Finally, we will use innovative methods throughout these studies, thus advancing the ability to study epigenetic regulation in the context of mammalian developmental physiology.

描述（由申请人提供）：肝脏的生长和功能分化对妊娠晚期胎儿代谢、围产期过渡和新生儿代谢适应至关重要。胎儿肝脏发育的生物学也对胎儿体细胞生长的调节、肝癌发生和肝病的细胞治疗有影响。我们的实验室长期以来一直专注于啮齿动物妊娠后期的肝脏发育。在这样做的过程中，我们已经确定了胎肝细胞表型，其由调节胎肝细胞生长、增殖和基因表达的信号通路定义。最近，我们证明了妊娠晚期胎鼠肝细胞具有关键的肝细胞标志物亮氨酸氨基肽酶（Leucine amino peptidase，AAP）的能力，以重建受损的成年肝脏。这是成年大鼠肝细胞所不具有的能力。目前的建议是基于中心的假设，组蛋白变体和组蛋白翻译后修饰（PTM），通过对染色质结构的影响，占妊娠晚期胎鼠肝细胞的信号表型和这种表型的持久性移植到成年肝脏微环境。该项目的长期目标是确定解释胎肝细胞新特征的遗传和表观遗传机制，从而将对胎肝发育的理解应用于开发基于细胞的肝病治疗。这一目标将通过三个具体目标来实现。具体目标1是通过检查在胎儿晚期与成人生命期间肝脏中的染色质结构、组蛋白变体和组蛋白PTM来鉴定胎儿肝细胞表观遗传特征。具体目标2是表征在胎儿到成人过渡期间肝脏中的组蛋白变体、组蛋白PTM、染色质结构和关键生长调节基因的调节之间的功能关系。这一目标将测试特定组蛋白变体和PTM与关键生长调节基因的发育变化相关的假设。在具体目标3中，我们将评估目标1和2中鉴定的表观遗传特征在定义和维持妊娠晚期胎鼠肝细胞重新填充受损成年大鼠艾弗的能力中的作用。该目的将检验以下假设：胎肝表观遗传标记是具有肝细胞和胆管标志物的胎肝细胞亚群的特征，并且该表观遗传标记在移植前和移植后均存在。这些目标的完成将提供对决定发育中肝脏细胞行为的分子机制的深入了解，同时推进肝病细胞治疗的发展。该项目在多个方面具有创新性。我们将产生关于肝脏发育过程中基因表达的表观遗传调控的新信息。在这样做的过程中，我们将描述一个以前未鉴定的，多能细胞群在胎儿肝脏，使受伤的成人肝脏再生最后，我们将在这些研究中使用创新的方法，从而提高在哺乳动物发育生理学背景下研究表观遗传调控的能力。